Or

Open access

NEWS - Hematology

Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery – New England Journal of Medicine (free for a limited period)

“In moderate-to-high-risk patients undergoing cardiac surgery, six-month outcomes show that a restrictive red-cell transfusion strategy is noninferior to a liberal strategy” (via @NEJM see Tweet with Visual Abstract)

 


Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016 – JAMA Oncology (free)

“Global incident cases of multiple myeloma more than doubled from 1990-2016 w/incident cases increasing by 126%. The largest increase was in middle-SDI countries, particularly E. Asia with a 262% increase in incidence cases”. (via @IHME_UW see Tweet)

 


Antifibrinolytics for heavy menstrual bleeding – Cochrane Library (link to abstract and summary)

“Antifibrinolytics appear effective tor treating for heavy menstrual bleeding, without substantially increasing the rate of adverse events” (via @CochraneLibrary see Tweet)

 


Clinical Practice Guideline: Iron Deficient Anemia – Toward Optimized Practice (TOP) (free PDF)

See also: Summary (free PDF)

Related: see all TOP Clinical Practice Guidelines, a practical resource for Family Physicians at the point of care.

 


Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study – Journal of the American Heart Association (free)

“Composite rates of recurrence and major bleeding were 12.4% in patients who initiated NOACs within 2 days after acute stroke, 2.1% in those who initiated NOACs between 3 and 14 days, and 9.1% in patients who initiated NOACs >14 days after acute stroke. Future randomized studies to assess timing of initiation and choice of agent in patients with acute stroke and AF are warranted”.

 



Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years – JAMA Internal Medicine (free)

“In this population-based cohort study of 1.256.725 persons, there was a significantly lower age- and sex-adjusted incidence rate ratio of cancer among warfarin users vs nonusers”.

 


Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis – The BMJ (free)

“Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden should be considered for antepartum or postpartum thrombosis prophylaxis, or both”.

 


FDA News Release: FDA approval brings first gene therapy to the United States (free)

Commentaries: A $475,000 cancer drug: Wall Street sees ‘bargain’; patients see ‘completely broken’ system – HealthNewsReview (free) FDA Approves First CAR-T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia – National Institutes of Health (free) AND FDA Approves First Gene-Altering Leukemia Treatment, Costing $475.000 – New York Times (10 articles per month are free) AND The FDA Approves a Landmark Cancer Drug – The Atlantic (free)

“…is a cancer therapy that represents several things at once: a game-changing way to treat cancer through genetic engineering, a novel paradigm for the biotech business, and the latest turn in the debate over just how astronomically expensive a life-saving therapy can be”. (from The Atlantic)

 


Deferasirox for managing iron overload in people with thalassaemia – Cochrane Library (free)

Full review: Deferasirox for managing iron overload in people with thalassaemia – Cochrane Library (link to abstract – $ for full-text)

Iron chelation with oral Deferasirox (instead of injected deferoxamine) may offer an important treatment option for people with thalassaemia and secondary iron overload.

 


Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update. Comparative Effectiveness Review – Agency for Healthcare Research and Quality (free report and summary)

See also: Executive summary (free PDF)

Source: ACP Journal Wise ($ resource to find articles of interest)

Comprehensive review on the evidence regarding thromboembolism prophylaxis in major orthopedic surgery.

 


Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review – Blood (link to abstract – $ for full-text)

Source: Direct Oral Anticoagulants for Heparin-Induced Thrombocytopenia – Journal Watch ($)

This literature review and observational study suggest direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) are safe and effective for the treatment of Heparin-induced Thrombocytopenia.

 


Page 1 of 212
Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

Powered by Google TranslatorTranslator

 

Weekly or Less Often  (English Only)
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •